1
|
Smythe MA, Koerber JM, Roberts A, Hoffman JL, Batke J. Hospital Acquired Venous Thromboembolism: A Preventability Assessment. Hosp Pharm 2024; 59:183-187. [PMID: 38450351 PMCID: PMC10913888 DOI: 10.1177/00185787231198164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/08/2024]
Abstract
Background: The American Heart Association has a call to action to reduce hospital acquired venous thromboembolism (HA-VTE) by 20% by the year 2030. There is increasing recognition that quality improvement initiatives for VTE reduction should focus on reducing potentially preventable HA-VTE. The objective of our study was to determine what proportion of HA-VTE events are potentially preventable. Methods: This was a retrospective, single center pilot study of 50 patients with HA-VTE. Seven preventability factors were identified with a focus on VTE prescription and administration. Data were extracted through chart review using a systematic data collection form. The primary endpoint was the proportion of patients with potentially preventable HA-VTE. Descriptive statistics were used. Results: The median age was 66 years with an admission VTE risk level of moderate-high in 94%. Potentially preventable HA-VTE was found in 40% of cases. Missed doses occurred in 29.8% with a median of 2 missed doses and a range of 1 to 20. Patient refusal was the most common reason for missed doses in 71%. Delays in initiation occurred in 12.7%. Sixty percent of those on mechanical prophylaxis only had nonadherence. Conclusion: Forty percent of HA-VTE cases were potentially preventable. Missed doses was the most common preventability factor identified with patient refusal accounting for most missed doses.
Collapse
Affiliation(s)
- Maureen A. Smythe
- Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA
- Wayne State University, Detroit, MI, USA
| | - John M. Koerber
- Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA
- Wayne State University, Detroit, MI, USA
| | - Amanda Roberts
- Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA
- Henry Ford Macomb Hospital, Clinton Township, MI, USA
| | - Janet L. Hoffman
- Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA
- Wayne State University, Detroit, MI, USA
| | - Jason Batke
- Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA
| |
Collapse
|
2
|
Booth JP, Hartman AD. Developing a Comprehensive Framework of Safeguarding Strategies to Address Anticipated Errors With Organizational High-Alert Medications. Hosp Pharm 2024; 59:47-55. [PMID: 38223857 PMCID: PMC10786060 DOI: 10.1177/00185787231185871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2024]
Abstract
Purpose: To describe the development of a comprehensive framework of safeguarding strategies to address observed/anticipated errors with organizational high-alert medications. Methods: Observed/anticipated errors were identified for organizational high-alert medications and medication classes based on a review of external literature and alerts as well as internal voluntary error reporting. Anticipated or frequently reported errors were categorized into common cause error types. Error reduction strategies to address each common cause error were identified in collaboration with medication safety specialists and specialty practice pharmacists. Results: The review of externally and internally reported errors identified 101 observed/anticipated common cause errors across the 19 high-alert medication classes (median 5 error types per medication class, interquartile range 3-6). Safeguarding strategies specific to high-alert medications were identified in the following domains: separate or sequestered storage; restricted ordering; active alerts; dispensing in patient-specific dosing, unit of use, or unit-dose packaging; dispensing from pharmacy only; auxiliary labeling; level of care restriction; required monitoring; independent double checks; certification/privileging of staff; specific guidelines for use/monitoring; and other/miscellaneous. Identification of the observed/anticipated errors and the associated safeguarding strategies facilitated the development of a comprehensive tool and visual framework for addressing common cause errors associated with organizational high-alert medications. Conclusion: A comprehensive framework of safeguarding strategies to address anticipated errors with organizational high-alert medications is proposed. Although individual safeguards are institution-specific, the framework can be leveraged by all hospitals in order to take inventory of error-reduction strategies and prospectively identify gaps to address common cause errors.
Collapse
Affiliation(s)
| | - Amber D. Hartman
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
| |
Collapse
|
3
|
Agedal KJ, Steidl KE, Burgess JL, Seabury RW, Wojnowicz SR. Does circle priming improve smart infusion pump and electronic health record interoperability for chemotherapy in a pediatric hematology/oncology setting? J Oncol Pharm Pract 2024; 30:159-164. [PMID: 37078113 DOI: 10.1177/10781552231170769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/21/2023]
Abstract
INTRODUCTION The objective of this project was to assess the percentage of interoperability compliance within our pediatric hematology/oncology patient care areas for intravenous chemotherapy medications before and after the implementation of circle priming. METHODS We conducted a retrospective quality improvement project at an inpatient pediatric hematology/oncology floor and outpatient pediatric infusion center before and after implementation of circle priming. RESULTS There was a statistically significant increase in percent interoperability compliance for the inpatient pediatric hematology/oncology floor from 4.1% prior to implementation of circle priming to 35.6% after (odds ratio 13.1 (95% CI, 3.96-43.1), p < 0.001), as well as for the outpatient pediatric infusion center from 18.5% to 47.3%, respectively (odds ratio 3.9 (95% CI, 2.7-5.9), p < 0.001). CONCLUSION Implementation of circle priming has significantly increased the percentage of interoperability compliance for intravenous chemotherapy medications in our pediatric hematology/oncology patient care areas.
Collapse
Affiliation(s)
- Kaitlyn J Agedal
- Department of Pharmacy, Upstate University Hospital, Syracuse, New York, USA
| | - Kelly E Steidl
- Department of Pharmacy, Upstate University Hospital, Syracuse, New York, USA
- Department of Pediatrics, Upstate Medical University, Syracuse, New York, USA
| | - Jeni L Burgess
- Department of Pharmacy, Upstate University Hospital, Syracuse, New York, USA
| | - Robert W Seabury
- Department of Pharmacy, Upstate University Hospital, Syracuse, New York, USA
| | - Sarabeth R Wojnowicz
- Department of Pharmacy, Upstate University Hospital, Syracuse, New York, USA
- Department of Medicine, Upstate Medical University, Syracuse, New York, USA
| |
Collapse
|
4
|
Elste JM, Ipema HJ, Denton C, Munir F, Alomari R, Dazy A, Macrito R, Szydlowski N. Light-Sensitive Injectable Prescription Drugs-2022. Hosp Pharm 2023; 58:448-475. [PMID: 37711411 PMCID: PMC10498972 DOI: 10.1177/00185787221133804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/16/2023]
Abstract
This chart is an update to the 2014 article published in Hospital Pharmacy on injectable drugs that require protection from light. To update the chart, an online search of the FDALabel database was performed from inception through July 31, 2022 using the terms "protect" OR "light." After filtering out drugs with non-injectable routes of administration, the list of generic drug names was combined with the 2014 list and duplicates were removed. The resulting list of drugs was then reviewed to determine whether the drugs require protection from light during storage, preparation, or administration. The reader should always consult the Food and Drug Administration-approved prescribing information for the most up-to-date information regarding the need for protection from light.
Collapse
Affiliation(s)
- Jessica M. Elste
- University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA
| | - Heather J. Ipema
- University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA
| | - Christie Denton
- University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA
| | - Faria Munir
- University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA
| | - Ruba Alomari
- University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA
| | - Anna Dazy
- University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA
| | - Rosa Macrito
- University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA
| | - Nicole Szydlowski
- University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA
| |
Collapse
|
5
|
Phelps KM, Langenderfer RL, NeSmith BB, Ritter MS, Timmons ML, McDonald EM, Servais TK. Evaluation of Pharmacy Resident-Driven Medication Reconciliation on Patients at High Risk of Hospital Readmission. Hosp Pharm 2023; 58:272-276. [PMID: 37216079 PMCID: PMC10192989 DOI: 10.1177/00185787221134694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Purpose: Pharmacists play a key role in preventing medication errors during transitions of care and preventing hospital readmissions through medication reconciliation (MR) programs. This study retrospectively evaluated the implementation of a standardized pharmacy residentdriven MR program for patients at high risk for readmission as defined by the Hospital Readmissions Reduction Program (HRRP). Methods: This was a single-center, retrospective cross sectional study of a pharmacy resident-driven MR program including patients at high risk of readmission defined by HRRP. The primary objective was to determine the number of inpatient regimen interventions identified during the MR. Secondary objectives include severity of interventions, number of medication discrepancies identified, types of interventions and discrepancies identified, and all-cause hospital readmission rates within 30 days of discharge.. Results: Fifty-three high-risk patients were included in the study. Pharmacy intervention recommendations were accepted by prescribers for nine patients (9/53; 17.0%) with a total of 13 accepted inpatient regimen interventions. The two most commonly identified medication classes for interventions were anticonvulsants (3/13; 23.1%) and antidepressants (6/13; 46.2%). Discrepancies on the admission MR were identified for 46 (46/53; 86.8%) patients with a median of three discrepancies per patient (interquartile range 2-4). The most common type of discrepancy was an incorrect or unnecessary drug. The 30-day all-cause readmission rate was 35.8% (19/53) for the total patient Conclusion: A pharmacy-resident driven MR program provided value in clarifying prior to admission medications and may help prevent drugrelated adverse events.
Collapse
Affiliation(s)
| | | | | | - Megan S. Ritter
- Bon Secours Saint Francis Health
System, Greenville, SC, USA
| | | | | | | |
Collapse
|
6
|
Erdfelder F, Ebach F, Zoller R, Walterscheid V, Weiss C, Kappler J, Görtzen-Patin J, Schmitt J, Freudenthal NJ, Müller A, Ksellmann A, Grigutsch D, Külshammer M, Füssel M, Zenker S. Implementation of 2D Barcode Medication Labels and Smart Pumps in Pediatric Acute Care: Lessons Learned. Appl Clin Inform 2023; 14:503-512. [PMID: 37075805 PMCID: PMC10322227 DOI: 10.1055/a-2077-2457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Accepted: 03/19/2023] [Indexed: 04/21/2023] Open
Abstract
BACKGROUND In pediatric intensive care, prescription, administration, and interpretation of drug doses are weight dependent. The use of standardized concentrations simplifies the preparation of drugs and increases safety. For safe administration as well as easy interpretation of intravenous drug dosing regimens with standardized concentrations, the display of weight-related dose rates on the infusion device is of pivotal significance. OBJECTIVES We report on challenges in the implementation of a new information technology-supported medication workflow. The workflow was introduced on eight beds in the pediatric heart surgery intensive care unit as well as in the pediatric anesthesia at the University of Bonn Medical Center. The proposed workflow utilizes medication labels generated from prescription data from the electronic health record. The generated labels include a two-dimensional barcode to transfer data to the infusion devices. METHODS Clinical and technical processes were agilely developed. The reliability of the system under real-life conditions was monitored. User satisfaction and potential for improvement were assessed. In addition, a structured survey among the nursing staff was performed. The questionnaire addressed usability as well as the end-users' perception of the effects on patient safety. RESULTS The workflow has been applied 44,111 times during the pilot phase. A total of 114 known failures in the technical infrastructure were observed. The survey showed good ratings for usability and safety (median "school grade" 2 or B for patient safety, intelligibility, patient identification, and handling). The medical management of the involved acute care facilities rated the process as clearly beneficial regarding patient safety, suggesting a rollout to all pediatric intensive care areas. CONCLUSION A medical information technology-supported medication workflow can increase user satisfaction and patient safety as perceived by the clinical end-users in pediatric acute care. The successful implementation benefits from an interdisciplinary team, active investigation of possible associated risks, and technical redundancy.
Collapse
Affiliation(s)
- Felix Erdfelder
- Staff Unit for Medical and Scientific Technology Development and Coordination, University Hospital Bonn, Bonn, Germany
- Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany
- Applied Mathematical Physiology (AMP) Lab, Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany
- Applied Medical Informatics (AMI) Lab, Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany
| | - Fabian Ebach
- Department of Neonatology and Pediatric Critical Care, University Hospital Bonn, Bonn, Germany
| | - Richard Zoller
- Staff Unit for Medical and Scientific Technology Development and Coordination, University Hospital Bonn, Bonn, Germany
| | - Verena Walterscheid
- Staff Unit for Medical and Scientific Technology Development and Coordination, University Hospital Bonn, Bonn, Germany
- Department of Neonatology and Pediatric Critical Care, University Hospital Bonn, Bonn, Germany
| | - Claudia Weiss
- Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany
| | - Jochen Kappler
- Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany
| | - Jan Görtzen-Patin
- Staff Unit for Medical and Scientific Technology Development and Coordination, University Hospital Bonn, Bonn, Germany
- Applied Medical Informatics (AMI) Lab, Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany
- Department of Internal Medicine I - Gastroenterology and Hepatology, Nephrology, Infectious Diseases, Endocrinology and Diabetology, University Hospital Bonn, Bonn, Germany
| | - Joachim Schmitt
- Department of Neonatology and Pediatric Critical Care, University Hospital Bonn, Bonn, Germany
| | - Noa J. Freudenthal
- Pediatric Cardiac Surgery at the German Pediatric Heart Centre in Bonn, University Hospital Bonn, Bonn, Germany
| | - A. Müller
- Department of Neonatology and Pediatric Critical Care, University Hospital Bonn, Bonn, Germany
| | - Anne Ksellmann
- Pediatric Cardiac Surgery at the German Pediatric Heart Centre in Bonn, University Hospital Bonn, Bonn, Germany
| | - Daniel Grigutsch
- Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany
- Applied Medical Informatics (AMI) Lab, Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany
| | - Manuel Külshammer
- Staff Unit for Medical and Scientific Technology Development and Coordination, University Hospital Bonn, Bonn, Germany
- Department of Neonatology and Pediatric Critical Care, University Hospital Bonn, Bonn, Germany
| | - Maike Füssel
- Staff Unit for Medical and Scientific Technology Development and Coordination, University Hospital Bonn, Bonn, Germany
- Department of Neonatology and Pediatric Critical Care, University Hospital Bonn, Bonn, Germany
| | - Sven Zenker
- Staff Unit for Medical and Scientific Technology Development and Coordination, University Hospital Bonn, Bonn, Germany
- Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany
- Applied Mathematical Physiology (AMP) Lab, Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany
- Applied Medical Informatics (AMI) Lab, Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany
| |
Collapse
|
7
|
Forshay CM, Mellett J, Worley MM, Carnes CA, Fernandes A, Jordan TA. Implementation and Evaluation of a Prior Authorization Workflow for New-Start Inpatient Medications in Preparation for Discharge. Hosp Pharm 2023; 58:188-193. [PMID: 36890956 PMCID: PMC9986573 DOI: 10.1177/00185787221127610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Purpose: Medications that require prior authorization can complicate the discharge planning process. This study implemented and evaluated a process for identifying and completing prior authorizations during the inpatient setting prior to patient discharge. Methods: A patient identification tool was developed within the electronic health record to alert the patient care resource manager of inpatient orders for targeted medications that frequently require prior authorization with the potential to delay discharge. A workflow process using the identification tool and flowsheet documentation was developed to prompt the initiation of a prior authorization, if necessary. Following hospital-wide implementation, descriptive data for a 2-month period was collected. Results: The tool detected 1353 medications for 1096 patient encounters over the 2-month period. The most frequent medications identified included apixaban (28.1%), enoxaparin (14.4%), sacubitril/valsartan (6.4%), and darbepoetin (6.4%). For the medications identified, there were 93 medications documented in the flowsheet data for 91 unique patient encounters. Of the 93 medications documented, 30% did not require prior authorization, 29% had prior authorization started, 10% were for patients discharged to a facility, 3% were for home medications, 3% were medications discontinued at discharge, 1% had prior authorization denied, and 24% had missing data. The most frequent medications documented in the flowsheet included apixaban (12%), enoxaparin (10%), and rifaximin (20%). Of the 28 prior authorizations processed, 2 led to a referral to the Medication Assistance Program. Conclusion: The implementation of an identification tool and documentation process can help improve PA workflow and discharge care coordination.
Collapse
Affiliation(s)
| | - John Mellett
- The Ohio State University Wexner
Medical Center, Columbus, OH, USA
| | - Marcia M. Worley
- The Ohio State University College of
Pharmacy, Columbus, OH, USA
| | - Cynthia A. Carnes
- The Ohio State University Wexner
Medical Center, Columbus, OH, USA
- The Ohio State University College of
Pharmacy, Columbus, OH, USA
| | - Andre Fernandes
- The Ohio State University Wexner
Medical Center, Columbus, OH, USA
| | - Trisha A. Jordan
- The Ohio State University Wexner
Medical Center, Columbus, OH, USA
| |
Collapse
|
8
|
Wei W, Felippi R, Abbasi G, Pinn T, Rose KS, Rana I. The Impact of Electronic Health Record Interventions on Patient Access to Post-Hospital Discharge Prescriptions. Hosp Pharm 2023; 58:212-218. [PMID: 36890959 PMCID: PMC9986571 DOI: 10.1177/00185787221130689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/05/2023]
Abstract
Purpose: Assess the impact of electronic health record interventions on patient access to post-hospital discharge prescriptions. Methods: Five interventions were implemented in the electronic health record to improve patient access to prescriptions after discharge from hospital: electronic prior authorization, alternative medication suggestions, order sets, mail order pharmacy alerts, and medication interchange instructions. This was a retrospective cohort study of patient responses from discharges during 6 months before the first intervention implementation and 6 months after the last intervention implementation documented in the electronic health record and a transition-in-care platform. Primary endpoint was the proportion of discharges with patient-reported issues that would have been prevented by the studied interventions out of number of discharges with at least one prescription, analyzed using Chi-squared test (level of significance .05). Results: Discharges with patient-reported issues that would have been prevented by the studied interventions decreased from 1.68 to 1.07 out of 1000 discharges with prescriptions (P < .001). Conclusion: Interventions in the electronic health record reduced barriers faced by patients to picking up prescriptions post-discharge from hospital, potentially leading to improved patient satisfaction and improved health outcomes. Important factors to consider for electronic health record intervention implementation are workflow development and intrusiveness of clinical decision support. Multiple targeted electronic health record interventions can improve patients' access to prescriptions after discharge from hospital.
Collapse
Affiliation(s)
- Wenfei Wei
- Department of Pharmacy, Houston
Methodist, Houston, TX, USA
| | - Rafael Felippi
- Physicians’ Alliance for Quality
Department, Houston Methodist, Houston, TX, USA
| | - Ghalib Abbasi
- Department of Pharmacy, Houston
Methodist, Houston, TX, USA
| | - Theresa Pinn
- Physicians’ Alliance for Quality
Department, Houston Methodist, Houston, TX, USA
| | - Kelly St. Rose
- Department of Pharmacy, Houston
Methodist, Houston, TX, USA
| | - Isha Rana
- Department of Pharmacy, Mount Sinai
Health System, New York, NY, USA
| |
Collapse
|
9
|
Rozycki E, Weiner A, Malvestutto C, Kman NE, Lustberg M, Dick M, Lehman KJ, Schieber A, Luca L, Jordan TA, Reed EE, Allen J, Parsons J, Nichols C, Conroy MJ. Evidence Based Scarce Resource Allocation During the COVID-19 Pandemic: A Case Study of Bamlanivimab Administration in the Emergency Department. Hosp Pharm 2022; 57:639-645. [PMID: 36081532 PMCID: PMC9445538 DOI: 10.1177/00185787211073466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/03/2023]
Abstract
Background: Patients presenting for emergency department (ED) evaluation may be appropriate for treatment with monoclonal antibodies for mild to moderate COVID-19. While many sites have implemented infusion centers for these agents, EDs will continue to evaluate these patients where appropriate identification and efficient infusion of eligible patients is critical. Objectives: Patients receiving bamlanivimab in the EDs of an academic medical center are described. The primary objective was to describe operational metrics and secondary objectives reported clinical outcomes. Methods: Patients receiving bamlanivimab and discharged from the ED were included from November 16, 2020 to January 16, 2021 in the retrospective, observational cohort. Primary outcome was adherence to institutional criteria. Secondary outcomes included ED visit metrics, clinical characteristics, and return visits within 30 days. Risk factors for return visits were assessed with regression. Results: One hundred nineteen patients were included. Most (71%) were diagnosed with COVID-19 during the ED visit and median symptom duration was 3(IQR 2-5) days. Median number of risk factors for progression to severe disease was 2 (IQR 1-2). Thirty percent had a documented abnormal chest x-ray. Institutional criteria adherence was 99.2%. Median time from ED room to bamlanivimab was 4 (IQR 3.1-5.2) hours. Thirty patients had return visit within 30 days; 19 were COVID-19 related. Two multivariable regression models were analyzed for COVID-19 related return visit. Characteristics on ED presentation were considered in Model I: male gender (OR 3.01[0.97-9.31]), age (per 10 years) (OR 1.49[1.05-2.12]), African-American race (OR 3.46[1.09-11.06]), and symptom duration (per day) (OR 1.34[1.05-1.73]). Model II included labs and imaging acquired in ED. In Model II, age (per 10 years) (OR 1.52[1.07-2.16]) and abnormal CXR (OR 5.74[1.95-16.9]) were associated with COVID-19 related return visits. Conclusions: Administration of bamlanivimab to ED patients can be done efficiently, with the potential to reduce COVID-19 related return visits. Age and abnormal imaging were independent predictors of COVID-19 return visits.
Collapse
Affiliation(s)
| | - Ashley Weiner
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | | | - Nicholas E Kman
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Mark Lustberg
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Michael Dick
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - K. Joy Lehman
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Ariane Schieber
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Lynne Luca
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Trisha A Jordan
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Erica E Reed
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - James Allen
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Jonathan Parsons
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Courtney Nichols
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Mark J Conroy
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
| |
Collapse
|
10
|
Colmerauer JL, Linder KE, Dempsey CJ, Kuti JL, Nicolau DP, Bilinskaya A. Impact of Order-Set Modifications and Provider Education Following Guideline Updates on Broad-Spectrum Antibiotic Use in Patients Admitted With Community Acquired Pneumonia. Hosp Pharm 2022; 57:496-503. [PMID: 35898261 PMCID: PMC9310309 DOI: 10.1177/00185787211055797] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/03/2023]
Abstract
Purpose: Following updates to the Infectious Diseases Society of America (IDSA) practice guidelines for the Diagnosis and Treatment of Adults with Community-acquired Pneumonia in 2019, Hartford HealthCare implemented changes to the community acquired pneumonia (CAP) order-set in August 2020 to reflect criteria for the prescribing of broad-spectrum antimicrobial therapy. The objective of the study was to evaluate changes in broad-spectrum antibiotic days of therapy (DOT) following these order-set updates with accompanying provider education. Methods: This was a multi-center, quasi-experimental, retrospective study of patients with a diagnosis of CAP from September 1, 2019 to October 31, 2019 (pre-intervention) and September 1, 2020 to October 31, 2020 (post-intervention). Patients were identified using ICD-10 codes (A48.1, J10.00-J18.9) indicating lower respiratory tract infection. Data collected included demographics, labs and vitals, radiographic, microbiological, and antibiotic data. The primary outcome was change in broad-spectrum antibiotic DOT, specifically anti-pseudomonal β-lactams and anti-MRSA antibiotics. Secondary outcomes included guideline-concordance of initial antibiotics, utilization of an order-set to prescribe antibiotics, and length of stay (LOS). Results: A total of 331 and 352 patients were included in the pre- and post-intervention cohorts, respectively. There were no differences in order-set usage (10% vs 11.3%, P = .642) between the pre- and post-intervention cohort, respectively. The overall duration of broad-spectrum therapy was a median of 2 days (IQR 0-8 days) in the pre-intervention period and 0 days (IQR 0-4 days) in the post-intervention period (P < .001). Patients in whom the order-set was used in the post-intervention period were more likely to have guideline-concordant regimens ([36/40] 90% vs [190/312] 60.9%; P = .003). Hospital LOS was shorter in the post-intervention cohort (4.8 days [2.9-7.2 days] vs 5.3 days [IQR 3.5-8.5 days], P = .002). Conclusion: Implementation of an updated CAP order-set with accompanying provider education was associated with reduced use of broad-spectrum antibiotics. Opportunities to improve compliance and thus further increase guideline-concordant therapy require investigation.
Collapse
|
11
|
Strube‐Lahmann S, Müller‐Werdan U, Klingelhöfer‐Noe J, Suhr R, Lahmann NA. Patient safety in home care: A multicenter cross-sectional study about medication errors and medication management of nurses. Pharmacol Res Perspect 2022; 10:e00953. [PMID: 35506209 PMCID: PMC9066068 DOI: 10.1002/prp2.953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Accepted: 04/02/2022] [Indexed: 11/09/2022] Open
Abstract
Studies assume that up to 30% of home care recipients are exposed to a possible medication error. For the home care sector, the study situation regarding such errors is limited. The aim of the study was to find out how often medication errors occur and whether they are related to training, quality assurance measures (use of the double-check principle (DCP)), and other structural conditions of home care services. A cross-sectional study was conducted, comprising 485 fully trained nurses of 107 randomly selected home care services. Potential influencing factors were analyzed in a multiple logistic regression model. Of 485 fully qualified nurses, 41.6% reported medication errors within a 12-month period, while 14.8% did not answer this question. Nurses who had attended medication training within the last 2 years compared to a longer period (frequently to rather rarely applied DCP); the odds ratio of not making medication-related errors was 1.79[1.42-3.09] (OR 3.13; [1.88-5.20]). Years of professional experience, amount of patients per shift, and type of work contract (full/part-time) were not statistically significantly associated with reported medication errors. Medication-related errors occur frequently in home care. Regular training and adequate quality management measures increase patient safety. Nursing managers and other responsible individuals of home care institutions have to make sure that nursing staff take part in regular medication training and apply the DCP when they give out medication in home care.
Collapse
Affiliation(s)
- Sandra Strube‐Lahmann
- Geriatrics Research Group [Forschungsgruppe Geriatrie]Charité – Universitätsmedizin Berlincorporate member of Freie Universität BerlinHumboldt‐Universität zu Berlin, and Berlin Institute of HealthBerlinGermany
- Akademie der Gesundheit Berlin/Brandenburg e.V.BerlinGermany
| | - Ursula Müller‐Werdan
- Geriatrics Research Group [Forschungsgruppe Geriatrie]Charité – Universitätsmedizin Berlincorporate member of Freie Universität BerlinHumboldt‐Universität zu Berlin, and Berlin Institute of HealthBerlinGermany
| | | | - Ralf Suhr
- Centre for Quality in Care [Zentrum für Qualität in der Pflege (ZQP)]BerlinGermany
| | - Nils Axel Lahmann
- Geriatrics Research Group [Forschungsgruppe Geriatrie]Charité – Universitätsmedizin Berlincorporate member of Freie Universität BerlinHumboldt‐Universität zu Berlin, and Berlin Institute of HealthBerlinGermany
- MSB Medical School BerlinBerlinGermany
| |
Collapse
|
12
|
Thomas JJ, Bashqoy F, Brinton JT, Guffey P, Yaster M. Integration of the Codonics Safe Label System ® and the Omnicell XT ® Anesthesia Workstation into Pediatric Anesthesia Practice: Utilizing Technology to Increase Medication Labeling Compliance and Decrease Medication Discrepancies While Maintaining User Acceptability. Hosp Pharm 2022; 57:11-16. [PMID: 35521011 PMCID: PMC9065523 DOI: 10.1177/0018578720970464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Background: Perioperative medication errors are recognized as a source of patient morbidity and mortality. Medication management systems with built-in scanning and label-printing functions that integrate with medication-dispensing cabinets have the potential to decrease medication administration errors by improving compliance with medication labeling. Whether these management systems will also improve periodic automatic replacement (PAR) inventory control and be accepted by users is unknown. We hypothesized that implementation of the Codonics Safe Label System®, an automated labeling system (ALS), would increase compliance with labeling guidelines and improve PAR inventory control by decreasing medication discrepancies while maintaining user acceptability in the OR. Methods: We audited a cohort of anesthesia workstations and electronic anesthesia records for 2 months to compare dispensed and administered medications and establish a discrepancy baseline. We also observed a convenience sample of syringes to evaluate labeling compliance. Post-implementation of the ALS, we repeated the audit. Finally, an anonymous survey was distributed electronically to providers to assess user acceptability. Results: Pre-implementation the average daily medication discrepancy rate was 9.7%, decreasing to 6.1% post-implementation (χ2 1 = 43.9; P < .0001). Pre-implementation 330 of 696 syringes (47.4%) were either missing a label or labeling elements. After implementation, 100% of all syringes received a label with the complete required labeling information (P < .0001). All respondents agreed or strongly agreed that the system was easy to use, accurate, met their needs, printed labels quickly, improved safety and efficiency, and was recommendable. Conclusion: The ALS significantly increased the rate of best-practice-compliant medication labeling while reducing medication inventory discrepancies. The system was highly accepted by providers.
Collapse
|
13
|
Altyar A, Sadoun SA, Aljohani SS, Alradadi RS. Evaluating Pharmacy Practice in Hospital Settings in Jeddah City, Saudi Arabia: Dispensing and Administration-2019. Hosp Pharm 2022; 57:32-37. [PMID: 35521022 PMCID: PMC9065526 DOI: 10.1177/0018578720970470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Purpose: To evaluate the dispensing and administration processes in hospital settings in Jeddah city, Saudi Arabia. Method: A questionnaire based on the annual ASHP national survey was distributed among 35 hospitals. The response rate was 60%. After a follow-up period of 6 months, the final questionnaire was collected in November 2019. Result: The survey had a 60% response rate. Most surveyed hospitals have centralized pharmacies (76.2%). Few hospitals reported the use of the Bar Code Medication Administration BCMA system (19.0%) to verify doses during dispensing, and only 28.6% use automated dispensing cabinets. The main method to check unit doses in pharmacies is the "technician fills/pharmacist checks" method, as reported by 76.2% of hospitals. Conclusion: The new technologies in the field of healthcare are impacting the practice of medication distribution. Hospital pharmacies in Jeddah, Saudi Arabia are implementing many changes to improve the medication-use system. However, more work has to be done to follow the leaders in the area of pharmacy practice.
Collapse
Affiliation(s)
- Ahmed Altyar
- King Abdulaziz University, Jeddah, Saudi Arabia,Ahmed Altyar, Faculty of Pharmacy, King Abdulaziz University, P.O. Box 80260, Jeddah 21441, Saudi Arabia.
| | | | | | | |
Collapse
|
14
|
Trapskin PJ, Sheehy A, Creswell PD, McCarthy DE, Skora A, Adsit RT, Rose AE, Bishop C, Bugg J, Iglar E, Zehner ME, Shirley D, Williams BS, Hood AJ, McElray K, Baker TB, Fiore MC. Development of a Pharmacist-Led Opt-Out Cessation Treatment Protocol for Combustible Tobacco Smoking Within Inpatient Settings. Hosp Pharm 2022; 57:167-175. [PMID: 35521012 PMCID: PMC9065528 DOI: 10.1177/0018578721999809] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Background: Although people who smoke cigarettes are overrepresented among hospital inpatients, few are connected with smoking cessation treatment during their hospitalization. Training, accountability for medication use, and monitoring of all patients position pharmacists well to deliver cessation interventions to all hospitalized patients who smoke. Methods: A large Midwestern University hospital implemented a pharmacist-led smoking cessation intervention. A delegation protocol for hospital pharmacy inpatients who smoked cigarettes gave hospital pharmacists the authority to order nicotine replacement therapy (NRT) during hospitalization and upon discharge, and for referral to the Wisconsin Tobacco Quit Line (WTQL) at discharge. Eligible patients received the smoking cessation intervention unless they actively refused (ie, "opt-out"). The program was pilot tested in phases, with pharmacist feedback between phases, and then implemented hospital-wide. Interviews, surveys, and informal mechanisms identified ways to improve implementation and workflows. Results: Feedback from pharmacists led to changes that improved workflow, training and patient education materials, and enhanced adoption and reach. Refining implementation strategies across pilot phases increased the percentage of eligible smokers offered pharmacist-delivered cessation support from 37% to 76%, prescribed NRT from 2% to 44%, and referred to the WTQL from 3% to 32%. Conclusion: Hospitalizations provide an ideal opportunity for patients to make a tobacco quit attempt, and pharmacists can capitalize on this opportunity by integrating smoking cessation treatment into existing inpatient medication reconciliation workflows. Pharmacist-led implementation strategies developed in this study may be applicable in other inpatient settings.
Collapse
Affiliation(s)
- Philip J. Trapskin
- University of Wisconsin, Madison, WI, USA,UW Health, Madison, WI, USA,UW School of Pharmacy, Madison, WI, USA
| | - Ann Sheehy
- University of Wisconsin, Madison, WI, USA,UW Health, Madison, WI, USA,UW Department of Medicine, Madison, WI, USA,UW School of Medicine and Public Health, Madison, WI, USA
| | - Paul D. Creswell
- University of Wisconsin, Madison, WI, USA,UW Department of Medicine, Madison, WI, USA,UW School of Medicine and Public Health, Madison, WI, USA,UW Center for Tobacco Research and Intervention (UW-CTRI), Madison, WI, USA,Paul D. Creswell, UW Center for Tobacco Research and Intervention (UW-CTRI), 1930 Monroe Street, Suite 200, Madison, WI 53706, USA.
| | - Danielle E. McCarthy
- University of Wisconsin, Madison, WI, USA,UW Health, Madison, WI, USA,UW Department of Medicine, Madison, WI, USA,UW School of Medicine and Public Health, Madison, WI, USA,UW Center for Tobacco Research and Intervention (UW-CTRI), Madison, WI, USA
| | - Amy Skora
- University of Wisconsin, Madison, WI, USA,UW Department of Medicine, Madison, WI, USA,UW School of Medicine and Public Health, Madison, WI, USA,UW Center for Tobacco Research and Intervention (UW-CTRI), Madison, WI, USA
| | - Rob T. Adsit
- University of Wisconsin, Madison, WI, USA,UW Department of Medicine, Madison, WI, USA,UW School of Medicine and Public Health, Madison, WI, USA,UW Center for Tobacco Research and Intervention (UW-CTRI), Madison, WI, USA
| | - Anne E. Rose
- University of Wisconsin, Madison, WI, USA,UW Health, Madison, WI, USA,UW School of Pharmacy, Madison, WI, USA
| | - Candace Bishop
- University of Wisconsin, Madison, WI, USA,UW Health, Madison, WI, USA,UW School of Pharmacy, Madison, WI, USA
| | - Jessica Bugg
- University of Wisconsin, Madison, WI, USA,UW Health, Madison, WI, USA,UW School of Pharmacy, Madison, WI, USA
| | - Emily Iglar
- University of Wisconsin, Madison, WI, USA,UW Health, Madison, WI, USA,UW School of Pharmacy, Madison, WI, USA
| | - Mark E. Zehner
- University of Wisconsin, Madison, WI, USA,UW Department of Medicine, Madison, WI, USA,UW School of Medicine and Public Health, Madison, WI, USA,UW Center for Tobacco Research and Intervention (UW-CTRI), Madison, WI, USA
| | - Daniel Shirley
- University of Wisconsin, Madison, WI, USA,UW Health, Madison, WI, USA,UW School of Medicine and Public Health, Madison, WI, USA
| | - Brian S. Williams
- University of Wisconsin, Madison, WI, USA,UW Health, Madison, WI, USA,UW Department of Medicine, Madison, WI, USA,UW School of Medicine and Public Health, Madison, WI, USA,UW Center for Tobacco Research and Intervention (UW-CTRI), Madison, WI, USA
| | - Adam J. Hood
- University of Wisconsin, Madison, WI, USA,UW School of Pharmacy, Madison, WI, USA
| | - Krista McElray
- University of Wisconsin, Madison, WI, USA,UW Health, Madison, WI, USA,UW School of Pharmacy, Madison, WI, USA
| | - Timothy B. Baker
- University of Wisconsin, Madison, WI, USA,UW Department of Medicine, Madison, WI, USA,UW School of Medicine and Public Health, Madison, WI, USA,UW Center for Tobacco Research and Intervention (UW-CTRI), Madison, WI, USA
| | - Michael C. Fiore
- University of Wisconsin, Madison, WI, USA,UW Health, Madison, WI, USA,UW Department of Medicine, Madison, WI, USA,UW School of Medicine and Public Health, Madison, WI, USA,UW Center for Tobacco Research and Intervention (UW-CTRI), Madison, WI, USA
| |
Collapse
|
15
|
Pitman S, Jones C, Polyak S, Taylor A, Cerven-Jenn D, Reist D. Exploring Cost Savings with Specialty Biologic Drugs Administered to Adult Inpatients with Inflammatory Bowel Disease. Hosp Pharm 2022; 57:112-116. [PMID: 35521007 PMCID: PMC9065510 DOI: 10.1177/0018578720985430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Background: Specialty infusion and self-injectable biologic drugs for the treatment of inflammatory bowel disease (IBD) are high-cost medications. When administered to hospital-admitted patients, these medications are not reimbursed on an individual basis but rolled into a per diem payment by most payers in the United States (US). Therefore, choosing to administer these medications in the inpatient setting may reveal negative financial implications for some health care institutions. Selecting an alternative site of care to administer these medications during the clinical management process may lead to cost savings. Objective: Review the clinical necessity of inpatient specialty biologic administrations for the treatment of IBD to identify and quantify potential cost saving opportunities. Methods: Using patient medical records at a US academic medical center, we retrospectively identified inpatient administrations of specialty infusion and self-injectable biologic medications for IBD treatment from June 1, 2016 to May 31, 2017. Guided by a standardized form, an evaluation team consisting of 3 of the investigators determined the clinical necessity of each specialty biologic medication administration within the inpatient setting. Costs and reimbursement rates for administration in both the inpatient and outpatient settings were procured and tabulated. Results: Seventeen inpatient specialty biologic administrations for IBD during the 12 month study period were identified. Of these, 11 administrations were given for the treatment of Crohn's disease (CD) and 6 for ulcerative colitis (UC). The evaluation team determined that 65% of these administrations were clinically necessary as inpatient administrations, and that 35% were not. The sum of the wholesale acquisition costs (WAC) for clinically necessary inpatient biologic administrations totaled $54 737, and the WAC for those administrations deemed not clinically necessary totaled $43 702. Further analysis of administration events revealed that the institution could have realized an estimated $13 817 in additional revenue above the cost of the drug if eligible inpatient biologic administrations had been received in the institution's outpatient clinic setting instead. Conclusion: Administering specialty biologic drugs for the treatment of IBD in the care setting best aligned with existing reimbursement structures may lead to institutional cost savings.
Collapse
|
16
|
Hertig J, Jarrell K, Arora P, Nwabueze J, Moureaud C, Degnan DD, Trujillo T. A Continuous Observation Workflow Time Study to Assess Intravenous Push Waste. Hosp Pharm 2021; 56:584-591. [PMID: 34720164 DOI: 10.1177/0018578720931754] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background: There are significant costs associated with proper controlled substance disposal, management, and regulatory compliance. Given the high abuse potential of fentanyl, hydromorphone, and morphine it is imperative that (1) product waste is minimized; and (2) waste procedures are followed to ensure safe disposal. Research is needed to better understand the financial and workforce impacts of drug waste on inpatient hospital units. The primary objective of this study was to quantify the waste associated with administering fentanyl, hydromorphone, and morphine via the intravenous push route. Two categories of waste were evaluated: (1) the quantity (mg/µg) of drug disposed; and (2) workforce time associated with the waste disposal process. Methods: A workflow time study design, a sub-set of continuous direct observation time motion studies, was employed to achieve the research objectives. A data collection tool was developed to capture medication type, waste amount, activity time stamps, total time, and number of interruptions at two separate study sites. Descriptive statistics were conducted on all the data measures. The number of assessments, total values, and mean values were reported for each drug (fentanyl, hydromorphone, and morphine) separately as well as grouped data. Results: A total of 669 distinct waste observations meeting inclusion criteria were collected during a study period of 15 days. In total, 207 mg of hydromorphone and 17 962.50 µg of fentanyl were wasted during this study. Nursing staff time associated with the wasting process totaled 50 990 seconds (849.83 minutes or 14.16 hours). A combined waste (loss) of approximately $1605.39 was associated with controlled substance wasting. The cost per dose wasted in this study was found to be $2.40 for all medications. When a yearly extrapolation model was applied to the four study units, the total combined product and workforce waste cost was $35 425. Conclusion: There are financially significant costs associated with wasting both the product and the valuable time of a skilled workforce. Optimizing product size, taking special note to match product availability with common practice use, would reduce the associated financial burden on our health-systems nationwide.
Collapse
|
17
|
AbuBlan RS, Awad W, Agha R, Hejawi N, Srouji H, Hammoudeh S, Nazer LH. Impacts of a Mail-Order Service for Refilling Prescriptions on Patient Satisfaction and Operational Load at a Comprehensive Cancer Center in Jordan. Hosp Pharm 2021; 56:543-549. [PMID: 34720159 DOI: 10.1177/0018578720928266] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background Mail-order services for refilling prescriptions for medications have been established in many countries and have increased patient satisfaction. We developed a mail-order service for the outpatient pharmacy of a comprehensive cancer center in Jordan. Objective To describe the implementation of a mail-order service and to report the impact of the service on patient satisfaction and the pharmacy workload. Methods A multidisciplinary team was formed to plan a mail-order service for refilling prescriptions for medications, and a survey was designed to evaluate patient satisfaction with the service. Patients were instructed to call the refill call center and order their medications at least 48 hours before their refill is due. The pharmacy workflow for refilling prescriptions was evaluated, and the time required with and without the mail-order service was documented, with a calculation of the time saved. Results At 1 year after the mail-order service had been established, 14 200 prescriptions had been refilled through the service, with the majority (97.5%) dispensed within 48 hours of the order time. As per the survey conducted with 219 patients, on the overall satisfaction, 69.4% reported being highly satisfied with the service and 27.9% reported being satisfied. The problems reported with the service were delay in arrival (n = 23, 10.5%), medication-related errors (n = 9, 4.1%), cash-related error (n = 1, 0.45%), improper storage condition (n = 1, 0.45%), and delivery to the wrong address (n = 4, 1.8%). The service was also associated with reduced overall time for processing in the outpatient pharmacy service; for patients receiving their medications from the pharmacy, resulting in reduced patients' overall waiting time (from 11.4 to 8.2 minutes). The service resulted in saving of 0.4 full-time employee at 1 year of implementation. Conclusions A mail-order service for refilling prescriptions within a hospital setting had positive outcomes on both patient satisfaction and the pharmacy workflow. The major issues were related to transportation and logistics.
Collapse
Affiliation(s)
| | - Wedad Awad
- King Hussein Cancer Center, Amman, Jordan
| | - Randa Agha
- King Hussein Cancer Center, Amman, Jordan
| | | | | | | | | |
Collapse
|
18
|
Abstract
Purpose: To assess chemical degradation of various liquid chemotherapy and opioid drugs in the novel RxDestruct™ instrument. Methods: Intravenous (IV) drug solutions for chemotherapy and pain management were prepared using 0.9% normal saline in Excel® bags to a final volume of 500 mL. We investigated duplicate IV solutions of methotrexate (0.1 mg/mL), etoposide (0.4 mg/mL), doxorubicin (0.25 mg/mL), cladribine (12.4 µg/mL), fentanyl (1.0 µg/mL), and hydromorphone (12.0 µg/mL) in this study. Solutions were poured into an automated instrument to undergo pulsatile chemical treatment (Fenton reactions) for 20 minutes, and then discharged from the instrument through a waste outlet. Extent of intact drug degradation was determined by measuring concentrations of drugs before entry into the instrument and after chemical treatment in the filtrate using high-performance liquid-chromatography with ultraviolet detection (HPLC-UV). Results: Following chemical reactions (Fenton processes) in the automated instrument, infusion solutions containing methotrexate, etoposide, doxorubicin, and cladribine had levels below the HPLC-UV limit of quantification (LOQ), indicating <50 ppb of each. This equated to >99.5%, 99.99%, 99.9%, and 99.8% intact drug loss, respectively. Likewise, processed samples of fentanyl and hydromorphone contained levels below the LOQ (78 and 98 ng/mL, respectively), indicating extensive degradation (>92.2% and 99.2% intact drug loss, respectively). Conclusion: The novel instrument was capable of degrading intact chemotherapy and opioid drugs prepared in infusion solutions to undetectable quantities by HPLC-UV. RxDestruct™ is a possible alternative for disposal of aqueous medication waste.
Collapse
Affiliation(s)
| | | | - Yan Ping Zhang
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ryan Roux
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Alan L Myers
- University of Texas Health Science Center, Houston, TX, USA
| |
Collapse
|
19
|
Cosimi RA, Howe ZW, Saum LM. Impact of Extended- Versus Intermittent-Infusion Cefepime on Clinical Outcomes in Hospitalized Patients. Hosp Pharm 2020; 56:302-307. [PMID: 34381265 DOI: 10.1177/0018578719893377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background: Pharmacodynamic models support potential improved antimicrobial pharmacokinetic and pharmacodynamic goal attainment in patients treated with extended-infusion (EI) versus intermittent-infusion (II) cefepime. Small clinical studies demonstrate inconsistent findings in patient outcomes, necessitating a deeper review of this administration method. Methods: This was a retrospective cohort study comparing patients receiving EI versus II cefepime between September 1, 2017, and March 31, 2018. The primary outcome was in-hospital all-cause mortality. Secondary objectives included length of hospital and ICU stay, time to defervescence, duration of therapy, duration of mechanical ventilation, and readmission rate. Subgroup analyses for the primary objective were conducted based on comorbid burden and isolate susceptibilities. Results: No statistically significant differences were noted in the 645 included patients for the primary outcome between the EI and II groups (7.8% vs 10.4%, P = .32). Median length of stay was 9 days (IQR 12) versus 11 days (IQR 14) (P = .30), respectively. In addition, statistical significance was not seen in any of the subgroups for the primary outcome including patients with APACHE II score ≥ 20 (17.4% vs 30.6%, P = .26) and for infections caused by Pseudomonas aeruginosa (5.9% vs 20.0%, P = .23) or Enterobacteriaceae (11.1% vs 20.0%, P = .13) with minimum inhibitory concentration (MIC) ≥ 4. Conclusion: No statistically significant differences were noted between EI and II groups, although benefits in specific subpopulations may exist when these results are correlated with findings from studies examining alternative antipseudomonal beta lactams.
Collapse
Affiliation(s)
| | | | - Lindsay M Saum
- Ascension - St. Vincent Health, Indianapolis, IN, USA.,Butler University, Indianapolis, IN, USA
| |
Collapse
|
20
|
Conliffe B, VanOpdorp J, Weant K, VanArsdale V, Wiedmar J, Morgan J. Impact of an Advanced Pharmacy Practice Experience Student-Run "Meds 2 Beds" and Discharge Counseling Program on Quality of Care. Hosp Pharm 2019; 54:314-322. [PMID: 31555007 DOI: 10.1177/0018578718791519] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Purpose: As health care progresses toward pay for performance reimbursement models and focus is placed on the patient as a consumer, health care systems must adapt by initiating new programs and services. This institution responded by implementing a "Meds 2 Beds" program integrating clinical services with dispensing and medication delivery during transitions of care. This study evaluates outcomes relevant to patients, health care providers, pharmacists, and administrators. Methods: This observational chart review evaluated the effectiveness of a "Meds 2 Beds" program from May 1, 2014, through December 1, 2015. Patients who participated in this program were matched 1:1 with controls who did not. The primary outcome was 30-day hospital readmission. Secondary outcomes included 30-day emergency department (ED) visits, patient satisfaction, and financial impact. Results: In this sample, 185 "Meds 2 Beds" patients were matched to 185 controls. Thirty day readmission occurred in 16 (8.7%) "Meds 2 Beds" cases and 19 (10.3%) controls (P = .71). Rates of 30-day ED visits were nonsignificantly reduced in cases (22 [11.9%] vs 33 [18.1%]; odds ratio = 0.62, P = .11) and occurred significantly later (11 vs 7 days, P = .03). Conclusions: This study showcases a creative medication delivery and discharge counseling program. The program provides financial benefit to the institution creating a direct revenue stream from prescription dispensing while highlighting a potential for reduced readmissions and ED visits (although a statistically significant difference was not demonstrated in this analysis). A similar model can be adopted by other health care institutions to improve the quality of patient care.
Collapse
Affiliation(s)
| | | | - Kyle Weant
- University of Louisville Hospital, KY, USA
| | | | | | | |
Collapse
|
21
|
Abstract
Background: Antimicrobial stewardship programs commonly utilize infectious diseases pharmacists to guide appropriate utilization of broad-spectrum antimicrobials. Strategies should be developed to increase staff pharmacist's participation in decreasing broad-spectrum antibiotic use. Objective: The purpose of this study was to determine the effectiveness of a pharmacy-driven 72-hour antimicrobial stewardship initiative. Methods: A pharmacy-driven 72-hour antibiotic review policy was implemented at a community hospital. Targeted antibiotics included ertapenem, meropenem, and daptomycin. The hospital's infectious diseases pharmacist provided policy education to staff pharmacists. All pharmacists provided prospective audit and feedback to physicians. Preimplementation and postimplementation data were collected through a retrospective chart review to analyze the impact of the initiative. Results: There were a total of 570 targeted antibiotic orders for review, of which 155 antibiotic orders met criteria for inclusion; 97 in the preimplementation group and 58 in the postimplementation group. Targeted antibiotic orders decreased postimplementation during the study period. Days of therapy per 1000 patient days decreased between the 2 groups, although this was statistically significant neither for the pooled targeted antibiotics nor for each individual antibiotic. There was a statistically significant increase in the number of appropriately prescribed targeted antibiotics from preimplementation compared to postimplementation (from 35% to 64%, P < .01). Pharmacist interventions documented for patients receiving the targeted antibiotics increased significantly during the intervention period (P < .01). In addition, there was a total of $28 795.96 in cost avoidance based on the difference in antibiotic use between the 2 groups. Conclusion: Implementation of a pharmacy-driven 72-hour broad-spectrum antibiotic review in a large community-based hospital resulted in a reduction in utilization and hospital spending and a significant increase in appropriate use of targeted antibiotics, while also increasing pharmacist engagement with antimicrobial stewardship.
Collapse
|
22
|
Altyar AE, Sadoun SA, Alradadi RS, Aljohani SS. Evaluating Pharmacy Practice in Hospital Settings in Jeddah City, Saudi Arabia: Prescribing and Transcribing-2018. Hosp Pharm 2019; 55:306-313. [PMID: 32999500 DOI: 10.1177/0018578719844707] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Purpose: The aim of this study was to evaluate the prescription and transcription processes in hospital settings in Jeddah city, Saudi Arabia. Method: A customized version of the original American Society of Health-System Pharmacists (ASHP) survey was distributed to a total of 26 hospitals in Jeddah city that fits our criteria starting from December 2017. Hospitals' names were adopted from the Ministry of Health and Jeddah Municipality websites. All questionnaires were collected in June 2018. After that, they were classified according to the type of care provided by the hospital, size, ownership, teaching affiliation, and accreditation. Data were entered electronically using Google forms, and then Microsoft Excel was used to conduct descriptive statistics. Results: The survey had a response rate of 57%. A strict formulary system was adopted in 53.3% of hospitals, and clinical practice guidelines were used to optimize medication use in 86.7% of hospitals. Pharmacists do not have the authority to write medication orders in about 86.7% of hospitals and only 40.0% of hospitals have pharmacists routinely assigned to patient care units. However, Pharmacists actively provided consultation, mostly in drug information (80.0%). Computerized prescriber order entry (CPOE) is used to receive medication orders electronically in 80.0% of hospitals, and electronic health record (EHR) is used in about 53.3% of hospitals and 50.0% of those hospitals have pharmacists who document their clinical intervention in EHR. Conclusion: Survey results suggest that pharmacists in hospital settings have not yet been positioned to improve the prescribing and transcribing components of the medication-use process.
Collapse
|
23
|
Prokes M, Root A. A Retrospective Analysis of Adherence to Risk Evaluation and Mitigation Strategies Requirements for Pulmonary Arterial Hypertension Drugs. Hosp Pharm 2018; 54:309-313. [PMID: 31555006 DOI: 10.1177/0018578718791509] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Purpose: The purpose of this quality-improvement project was to assess risk evaluation and mitigation strategies (REMS) program compliance for pulmonary arterial hypertension (PAH) drugs following the initiation of more rigid protocols and informatics changes. The primary objective of the study was to determine the effects of these changes on overall compliance of the REMS program requirements. Method: This was a single-center, retrospective evaluation of protocols and informatics updates that were developed to increase compliance with REMS programs for four drugs used to treat PAH. Two separate time periods were examined for comparison: the preinformatics period, January 2015 to February 2016, and the postinformatics period, October 2016 to April 2017. To be included in the study, patients must have been at least 18 years of age and have been ordered one of the following agents: riociguat, macitentan, bosentan, or ambrisentan. Results: Overall, 94 patients were evaluated with 50 in the preinformatics group and 44 in the postinformatics group. The overall mean age of included patients was 55 years, 57.9% of patients were white, 69.1% were female, and 43.6% were prescribed ambrisentan during the study period. The primary composite endpoint of adherence to REMS protocol (pregnancy tests performed within 30 days of medication initiation for female patients of childbearing potential, liver function tests [LFTs] ordered within 30 days of bosentan initiation, and initiation of therapy order documented by an attending provider enrolled in the REMS program) showed an overall improvement in the postinformatics period, 95% vs 71% (P = .07).There was a statistically significant increase in pregnancy tests performed within 30 days of medication order in the postinformatics period (36.4% vs 100%; P = .01). Furthermore, during the postinformatics period, the number of documented interventions (iVents) performed by a pharmacist was 90.9%. Conclusion: Initiation of more rigid ordering protocols for the endothelin receptor antagonists (macitentan, bosentan, or ambrisentan) and riociguat improved pharmacist and physician compliance with REMS requirements.
Collapse
Affiliation(s)
- Mackenzie Prokes
- Duke University Hospital, Durham, NC, USA.,UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA
| | - Adam Root
- Duke University Hospital, Durham, NC, USA
| |
Collapse
|
24
|
Muhammad S, Tomko JR, Wilson LM. Evaluation of the Incidence of Ibuprofen Administration in Alcohol and Opioid Detoxification Patients With Concomitant Thrombocytopenia. Hosp Pharm 2017; 53:41-43. [PMID: 29434386 DOI: 10.1177/0018578717736667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Purpose: The purpose of this study was to determine the incidence of ibuprofen administration in patients who are undergoing alcohol and opioid detoxification, and have concomitant alcohol-related thrombocytopenia. Methods: This was a single-center, cross-sectional, prospective, observational study. A daily manual review of electronic health records was conducted for patients admitted to the detoxification unit of the hospital. Patients who (1) were of age 18 years or more, (2) were ordered both alcohol and opioid detoxification protocols, and (3) had a platelet count of less than 150 000/µL were included in the study. The incidence of ibuprofen administration was evaluated. Results: Twenty-five patients were included in the analysis. More than 70% of patients had an active ibuprofen order and 50% of patients received ibuprofen. Patients with a platelet count of <100 000/µL were more likely to receive ibuprofen in the presence of an active ibuprofen order and received a higher dose of ibuprofen than patients who had a platelet count of ≥100 000/µL. Conclusion: This study highlights a potential medication safety concern in patients with alcohol-related thrombocytopenia who are unintentionally ordered ibuprofen. Future, long-term studies are warranted to further investigate this issue.
Collapse
Affiliation(s)
| | - John R Tomko
- University of Pittsburgh Medical Center, PA, USA
| | | |
Collapse
|